VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

ClinicalTrials.gov ID: NCT06249555

Public ClinicalTrials.gov record NCT06249555. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 9, 2026, 3:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

VOICE-Characterization of Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease Using Patient-Reported Outcome Measures: A Prospective Observational Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary aim of this study is to explore the time course of response to Vedolizumab in participants with CD as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference-short form (SF), as well as other PROMIS domain SFs (fatigue, anxiety, depression, sleep disturbance, physical function, and ability to participate in social roles and activities); other PRO measures will also be assessed.

Study identification

NCT ID: NCT06249555
Recruitment status: Active, not recruiting
Study type: Observational
Phase: Not listed
Lead sponsor: Alimentiv Inc.; Other
Enrollment: 300 participants

Conditions and interventions

Conditions

Crohn's Disease

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 19, 2024
Primary completion: Aug 31, 2026
Completion: Nov 30, 2026
Last update posted: Aug 20, 2026

2024 – 2026

United States locations

U.S. sites: 11
U.S. states: 10
U.S. cities: 11

Facility	City	State	ZIP	Site status
GI Alliance - Sun City	Sun City	Arizona	85351	—
Northwestern University	Evanston	Illinois	60611	—
University of Iowa	Iowa City	Iowa	52242	—
University Medical Center New Orleans	New Orleans	Louisiana	70112	—
Brigham and Women's Hospital	Chestnut Hill	Massachusetts	02467	—
University of North Carolina	Chapel Hill	North Carolina	27599	—
Cleveland Clinic Foundation	Cleveland	Ohio	44195	—
OR Clinic - East - GI	Portland	Oregon	97220	—
GI Alliance Research Fort Worth	Fort Worth	Texas	76104	—
GI Alliance Research Mansfield	Mansfield	Texas	76063	—
GI Alliance - Bellevue - Washington Gastroenterology	Bellevue	Washington	98004	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06249555, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 20, 2026 · Synced Sep 9, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06249555 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →